Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

The use of multiphase nonlinear mixed models to define and quantify long-term changes in serum prostate-specific antigen: data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Shoaibi A, Rao GA, Cai B, Rawl J, Hébert JR.

Ann Epidemiol. 2016 Jan;26(1):36-42.e1-2. doi: 10.1016/j.annepidem.2015.10.003. Epub 2015 Oct 28.

PMID:
26611771
2.

The many ways to make a luminal cell and a prostate cancer cell.

Strand DW, Goldstein AS.

Endocr Relat Cancer. 2015 Dec;22(6):T187-97. doi: 10.1530/ERC-15-0195. Epub 2015 Aug 25. Review.

4.

Gleason 6 Prostate Cancer: Translating Biology into Population Health.

Eggener SE, Badani K, Barocas DA, Barrisford GW, Cheng JS, Chin AI, Corcoran A, Epstein JI, George AK, Gupta GN, Hayn MH, Kauffman EC, Lane B, Liss MA, Mirza M, Morgan TM, Moses K, Nepple KG, Preston MA, Rais-Bahrami S, Resnick MJ, Siddiqui MM, Silberstein J, Singer EA, Sonn GA, Sprenkle P, Stratton KL, Taylor J, Tomaszewski J, Tollefson M, Vickers A, White WM, Lowrance WT.

J Urol. 2015 Sep;194(3):626-34. doi: 10.1016/j.juro.2015.01.126. Epub 2015 Apr 4. Review.

5.

Decision analysis of dutasteride use for patients with negative prostate biopsy.

Vickers AJ, Sjoberg DD.

Urology. 2015 Feb;85(2):337-41. doi: 10.1016/j.urology.2014.08.048.

6.

Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer.

Schalken J, Dijkstra S, Baskin-Bey E, van Oort I.

Ther Adv Urol. 2014 Dec;6(6):245-52. doi: 10.1177/1756287214545328. Review.

7.

Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.

Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco FJ Jr, Rabah DM, Klein EA, Ciezki JP, Gao T, Kattan MW, Stephenson AJ.

Eur Urol. 2015 Jun;67(6):1160-7. doi: 10.1016/j.eururo.2014.09.019. Epub 2014 Oct 6.

8.

Risk stratification of prostate cancer patients based on EPS-urine zinc content.

Medarova Z, Ghosh SK, Vangel M, Drake R, Moore A.

Am J Cancer Res. 2014 Jul 16;4(4):385-93. eCollection 2014.

9.

Kallikreins as biomarkers for prostate cancer.

Hong SK.

Biomed Res Int. 2014;2014:526341. doi: 10.1155/2014/526341. Epub 2014 Apr 7. Review.

10.

PSA Velocity in Risk Stratification of Prostate Cancer.

Bjurlin MA, Loeb S.

Rev Urol. 2013;15(4):204-6. Review. No abstract available.

11.

Prostate-specific antigen screening in prostate cancer: perspectives on the evidence.

Wilt TJ, Scardino PT, Carlsson SV, Basch E.

J Natl Cancer Inst. 2014 Mar;106(3):dju010. doi: 10.1093/jnci/dju010. Epub 2014 Mar 4. No abstract available.

12.

MALDI-target integrated platform for affinity-captured protein digestion.

Ahmad-Tajudin A, Adler B, Ekström S, Marko-Varga G, Malm J, Lilja H, Laurell T.

Anal Chim Acta. 2014 Jan 7;807:1-8. doi: 10.1016/j.aca.2013.08.051. Epub 2013 Sep 11.

13.

Racial differences in longitudinal changes in serum prostate-specific antigen levels: the Olmsted County Study and the Flint Men's Health Study.

Sarma AV, St Sauver JL, Jacobson DJ, McGree ME, Klee GG, Lieber MM, Girman CJ, Hollingsworth JM, Jacobsen SJ; Urologic Diseases in America Project.

Urology. 2014 Jan;83(1):88-93. doi: 10.1016/j.urology.2013.08.025. Epub 2013 Oct 16.

14.
15.

Temporal changes in the clinical approach to diagnosing prostate cancer.

Hilton WM, Padalecki SS, Ankerst DP, Leach RJ, Thompson IM.

J Natl Cancer Inst Monogr. 2012 Dec;2012(45):162-8. doi: 10.1093/jncimonographs/lgs038.

16.

Reconciling primary care and specialist perspectives on prostate cancer screening.

Hoffman RM, Barry MJ, Roberts RG, Sox HC.

Ann Fam Med. 2012 Nov-Dec;10(6):568-71. doi: 10.1370/afm.1399.

17.

Testosterone replacement and prostate cancer.

Ramasamy R, Fisher ES, Schlegel PN.

Indian J Urol. 2012 Apr;28(2):123-8. doi: 10.4103/0970-1591.98449.

18.

PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer.

Vickers AJ, Brewster SF.

Br J Med Surg Urol. 2012 Jul 1;5(4):162-168.

19.

Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.

Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H, Hugosson J.

J Clin Oncol. 2012 Jul 20;30(21):2581-4. doi: 10.1200/JCO.2011.40.4327. Epub 2012 Jun 18. No abstract available.

20.

Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics.

Carter HB.

Asian J Androl. 2012 May;14(3):355-60. doi: 10.1038/aja.2011.141. Epub 2012 Feb 20. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk